Objective: This study aimed to validate a magnetic resonance imaging (MRI) staging classification that preoperatively assessed the relationship between tumor and the low rectal cancer surgical resection plane (mrLRP). Background: Low rectal cancer oncological outcomes remain a global challenge, evidenced by high pathological circumferential resection margin (pCRM) rates and unacceptable variations in permanent colostomies. Methods: Between 2008 and 2012, a prospective, observational, multicenter study (MERCURY II) recruited 279 patients with adenocarcinoma 6 cm or less from the anal verge. MRI assessed the following: mrLRP ''safe or unsafe,'' venous invasion (mrEMVI), depth of spread, node status, tumor height, and tumor quadrant. MRI-based treatment recommendations were compared against final management and pCRM outcomes. Results: Overall pCRM involvement was 9.0% [95% confidence interval (CI), 5.9-12.3], significantly lower than previously reported rates of 30%. Patients with no adverse MRI features and a ''safe'' mrLRP underwent sphincter-preserving surgery without preoperative radiotherapy, resulting in a 1.6% pCRM rate. The pCRM rate increased 5-fold for an ''unsafe'' compared with ''safe'' preoperative mrLRP [odds ratio (OR) ¼ 5.5; 95% CI, 2.3-13.3)]. Posttreatment MRI reassessment indicated a ''safe'' ymrLRP in 33 of 113 (29.2%), none of whom had ypCRM involvement. In contrast, persistent ''unsafe'' ymrLRP posttherapy resulted in 17.5% ypCRM involvement. Further independent MRI assessed risk factors were EMVI (OR ¼ 3.8; 95% CI, 1.5-9.6), tumors less than 4.0 cm from the anal verge (OR ¼ 3.4; 95% CI, 1.3-8.8), and anterior tumors (OR ¼ 2.8; 95% CI, 1.1-6.8).
I n rectal cancer management, an incomplete cancer resection, identified by histopathological circumferential resection margin (pCRM) involvement, results in increased local recurrence and poor oncological outcomes. 1, 2 Low rectal cancer, defined as adenocarcinoma less than 6 cm from the anal verge, accounts for one third of all rectal cancers. pCRM involvement occurs in 20% to 36% of low rectal cancer surgical specimens, which is significantly worse than resection outcomes for mid and upper rectal cancers. [3] [4] [5] [6] These poor outcomes are attributed to suboptimal traditional abdominoperineal excision (APE) techniques that fail to achieve an adequate CRM at the distal mesorectum and at the sphincter complex. 4, 5 In addition, the surgical decision making between restorative resection and an APE has been inconsistent. 7 From the patient's perspective, this has led to unacceptable variations in permanent colostomy rates. 7 Hence, low rectal cancer management is a unique challenge due to poor oncological outcomes and high permanent colostomy rates.
A curative low rectal cancer restorative resection requires both the mesorectal fascia plane and the intersphincteric plane to be clear of tumor ( Fig. 1A-D) . The MERCURY study prospectively validated the ability of high-resolution magnetic resonance imaging (MRI) to preoperatively assess the ''tumor-mesorectal fascia relationship.'' 3, 8 No preoperative staging system to assess the intersphincteric FIGURE 1. A, Diagrammatic coronal oblique view through long-axis of the anal canal. Low rectal cancer is defined as adenocarcinoma with an inferior tumor edge less than 6 cm from the anal verge, anatomically represented by a line between the origins of the levator muscle (horizontal beige line). 39 The horizontal black line (1 cm above puborectalis sling) represents the site between the mesorectal fascia plane and the intersphincteric plane. MRI evaluation of the mesorectal fascia (dashed green line) has been validated previously. 3 This study aimed to validate a previously reported technique for MRI assessment of the intersphincteric plane (dashed red line). 9 Low rectal cancer circumferential resection margin involvement may occur at the mesorectal fascia plane or at the intersphincteric plane (B). When tumor extends beyond muscularis propria/internal sphincter the intersphincteric plane is ''unsafe'' (C); therefore, preoperative therapy and an ELAPE (dashed blue line) is recommended. When the intersphincteric plane is ''safe'' (D), an intersphincteric resection (dashed green line) AE anastomosis is feasible. plane has been prospectively validated. If tumor invades the intersphincteric plane, sphincter excision and a permanent stoma are needed to achieve a clear pCRM. Therefore, currently, it is not possible to preoperatively assess the feasibility of a restorative resection or quantify the risk of pCRM involvement in low rectal cancer. An MRI staging system to assess tumor-intersphincteric plane relationship has been developed ( Figs. 2A, B ). 9 This staging system was retrospectively tested in patients with low rectal cancer from the MERCURY study; tumor extending into the intersphincteric plane had a 17-fold increased risk of pCRM involvement. 9 The MER-CURY II study was designed to prospectively validate this MRI low rectal cancer staging system. This MRI assessment guided preoperative decisions by identifying tumors at risk of pCRM involvement. The primary aim was to reduce low rectal cancer pCRM involvement to less than 15% by using MRI planning to determine the relationship of tumor to both the mesorectal fascia and the intersphincteric plane. This information allows a clear pCRM to be achieved through appropriate selection for preoperative therapy and choosing the correct plane of surgery.
PATIENTS AND METHODS

Eligibility for Enrollment
The prospective, observational, multicenter MERCURY II low rectal cancer study (NCT02005965) was approved by UK research and ethics committee (REC 07/Q1702/75) and local review boards in Aarhus, Belgrade, Berlin, and Dresden. Consecutive patient enrollment occurred between January 2008 and March 2012. Eligibility criteria included adenocarcinoma with distal margin at or below 6.0 cm from anal verge on clinical examination and MRI. Exclusion criteria were pregnancy, previous pelvic malignancy, pelvic radiotherapy, pelvic floor surgery, or contraindicated MRI.
Radiological Assessment
High-resolution pelvic MRI was performed according to the MERCURY protocol. 10 Twenty-one designated radiologists (7-18 years of experience) from 14 centers prospectively proforma reported MRIs for tumor height (determined by distance from the inferior tumor edge to the anal verge on sagittal MRI view), tumor quadrant (defined by the site of maximal invasion on axial MRI), mrT stage (mrT1-submucosa invasion, T2-muscularis propria invasion, T3a&b < 5 mm beyond muscularis propria, T3c&d ! 5 mm beyond muscularis propria, T4 invasion into adjacent structure, or perforating peritoneum 11 ), mrN status [morphological rather than size criteria determined whether a node was benign or malignantmalignant nodes require irregular outlines or internal signal heterogeneity (mrN1 0-3 nodes, mrN2 ! 4 nodes) 11 ], and extramural venous invasion (tumor signal intensity expanding a vessel 12 ).
MRI Low Rectal Cancer Plane Staging
As routine current practice, radiologists reported the relationship of the tumor to the mesorectal fascia. All MERCURY II radiologists underwent workshop training to implement a previously developed staging system 9 assessing the intersphincteric plane ( Figs. 2A, B ). MRI intersphincteric plane ''safe'' tumors do not involve the intersphincteric plane or levator muscle. MRI intersphincteric plane ''unsafe'' tumors extend into the intersphincteric plane, 1 mm or less of the levator ani or involve adjacent structures such as the external sphincter. By combining the previously validated assessment of the mesorectal fascia with intersphincteric plane staging, for the first time, radiologists were able to assess the entire low rectal cancer plane ( Fig. 1A-D ). Combined staging of the intersphincteric plane and the mesorectal fascia plane was termed MRI low rectal plane (mrLRP). Hence, low rectal cancer threatening mesorectal fascia or the intersphincteric plane was termed mrLRP unsafe. Recommended surgical techniques were advocated according to MRI staging of the operative plane (Table 1) .
When preoperative therapy was utilized, posttreatment MRI reassessment of all tumor characteristics occurred (posttreatment staging was denoted by ''y'' prefix). Posttreatment assessment included low rectal cancer plane (ymrLRP) restaging and evaluation of treatment response using MRI tumor regression grade (mrTRG), as previously described. 13 A ''good response'' was defined as mrTRG1-2 and a tumor regressing from an mrLRP unsafe plane to a ymrLRP safe plane.
Treatment and Surgery
Treatment decisions were made by multidisciplinary cancer teams. Preoperative therapy was recommended for adverse radiological features: an unsafe intersphincteric plane, tumor less than FIGURE 2. A, B, A high-resolution, coronal, oblique MRI image through long-axis of the anal canal for 2 different low rectal cancers. A, A tumor confined to the muscularis propria (y). The MRI assessed low rectal cancer resection plane (mrLRP) appears ''safe,'' suggesting an intersphincteric resection is feasible. B, The tumor (¥) appears to breach the muscularis propria and is invading the distal mesorectum and intersphincteric plane. This tumor is mrLRP ''unsafe'' and an intersphincteric resection would be high-risk for pCRM involvement; therefore, an ELAPE was suggested.
1 mm from mesorectal fascia CRM, !mrT3c, mrN2, or mrEMVI. The policy for high-risk stage II and all stage III rectal cancers was to offer adjuvant chemotherapy.
A standardized technique for high-quality mesorectal dissection was used. 14 An extralevator APE (ELAPE) was recommended for tumors extending beyond the intersphincteric plane, whereby a wider resection margin at the level of puborectalis was achieved by an extended excision that included a cuff of the levator muscle ( Fig. 1C ). [15] [16] [17] [18] Protocol pathway deviations are recorded in Figure 3 .
Histopathological Assessment
Specialist colorectal histopathologists at each center (26 in total with 5-25 years of experience) applied prospective proforma reporting by TNM5 classification and current UK guidelines. 19 To enable MRI comparison with histopathology additional detail relating to planes of excision (mesorectum and sphincters), tumor orientation and relationship to sphincter complex were recorded (Appendix available at: http://links.lww.com/SLA/A753). Histopathologically involved circumferential resection margin (pCRM) was defined as tumor 1 mm or less from the resection plane. 20 An ELAPE was distinguished from a ''standard'' APE (sAPE) by operation record, confirmed by the presence (ELAPE) or absence (sAPE) of a cuff of the levator muscle on pathological examination. For quality control, specimens were routinely photographed, auditing mesorectal dissection quality, 21 and in APEs, tissue volume at the puborectalis level.
Statistical Analysis
Demographic and outcome data were compared as proportions by the x 2 test and ordered categorical variables by the Mann-Whitney U test. mrLRP status (safe and unsafe) was assessed against the pCRM outcome ( 1 or >1 mm) using the x 2 test; a significant difference was determined by P < 0.05 and by nonoverlapping 95% confidence intervals (CIs). Historically, with conventional staging, the low rectal cancer pCRM involvement rate has been 30%. 4, 5, 9 The primary endpoint was to reduce pCRM involvement from 30% to 15%. Sample size by single-stage Simon design (a ¼ 0.05; b ¼ 0.9), 22 with 25% dropout, required 271 patients. The odds ratio (ORs) and confidence limits for mrLRP resulting in pCRM involvement were calculated by using the Cox-Hinkley-Miettinen-Nurminen method. 23 Risk factors related to pCRM involvement were identified using univariate logistic regression. Continuous variables were grouped into subcategories according to the increasing pCRM risk and univariate logistic regression used to compare these with a reference category (Table 5 ). Multivariate regression analysis to adjust for multiple risk factors and their interactions was used, and subsequently derived coefficients were used to weight the predicted risk of an incomplete resection (pCRM involvement) ( Table 6) .
Although no external validation was performed, we internally validated the model by bootstrapping method, deemed most suitable for this sample size. 24 The Hosmer-Lemeshow statistic 25 evaluated the model calibration or goodness of fit (model's ability to assign the correct outcome probabilities to individual patients). Model discrimination (the ability to assign higher probabilities of pCRM involvement to patients who actually develop an involved margin) was measured by area under the receiver operator characteristic curve or c-index. Values exceeding 0.8 represent good discrimination. 26 Analyses were performed using SPSS (v21.0; IBM Corp, Armonk, NY).
Role of the Funding Source
The Pelican Cancer Foundation and NIHR Biomedical Research Centres had no role in study design, data collection, analysis, interpretation, or writing of the report. The corresponding author had full access to all study data and had final responsibility for the decision to submit for publication.
RESULTS
Patients
Fourteen units across Europe (Denmark, Germany, Serbia, and the United Kingdom) recruited 326 patients, with 38 exclusions and 9 additional dropouts, reported in Figure 3 . Thus, 279 patients were eligible for primary endpoint analysis. Median age was 65 years (IQR ¼ 55-73), with 99 females (35%) and median body mass index was 26 (IQR ¼ 23-28).
MRI Assessment of the Intersphincteric Plane
Surgery confined to the intersphincteric plane was performed in 142 (83.0%; 95% CI, 77.4-88Á7) of 176 MRI safe intersphincteric plane patients compared with 39 (39.39%; 95% CI, 29.6-49.2) of 103 MRI unsafe intersphincteric plane patients (P < 0.0001). Preoperative therapy was also offered selectively; 87 (49.4%; 95% CI, 42.0-56.9) of 176 MRI intersphincteric plane safe patients were treated compared with 83 (80.6%; 95% CI, 72.8-88.4]) of 103 MRI unsafe patients (P < 0.0001). Hence, the baseline intersphincteric 
MRI Assessment of the Low Rectal Plane (mrLRP)
This study has validated MRI staging system for evaluating the intersphincteric plane, which complements the previous MRI mesorectal fascia validation. 3 Hence, MRI assessment of the entire low rectal plane (mrLRP) is valid ( Table 2 ). All-cause pCRM involvement occurred in 8 (4.2%; 95% CI, 1.3-7.1) of 191 MRI safe mrLRP patients compared with 17 (19.3%; 95% CI, 10.9-27.7) of 88 unsafe mrLRP patients (P < 0.0001).
Overall pCRM Involvement
Overall, pCRM involvement occurred in 25 (9.0%; 95% CI, 5.6-12.3) of 279 patients; therefore, the primary endpoint of 15% or less pCRM involvement was achieved. Table 3 provides a comparison between recommended and actual treatment according to baseline mrLRP and adverse MRI features, where chemoradiotherapy (CRT) was given, the reassessed plane of surgery is reported (ymrLRP). This shows that 62 of 124 (50%) patients of the lowrisk mrLRP safe group followed MRI recommendations to proceed straight to surgery, with a resulting 1.6% pCRM involvement rate; overall, the pCRM rate for this group was 4.0%. In contrast, an unsafe baseline mrLRP with adverse MRI features resulted in a 17.7% pCRM involvement risk, which represented a 5-fold increase in pCRM involvement (OR ¼ 5.1; 95% CI, 1.8-14.5; P ¼ 0.0020). Following CRT, 41 patients underwent ELAPE/exenteration for adverse features and unsafe ymrLRP and the resulting pCRM involvement rate was 20.41%.
Preoperative MRI Predictors for pCRM Involvement
The demographics and tumor characteristics are reported in Table 4 according to the pCRM involvement rate, with univariate and multivariate regression analyses of key pCRM involvement predictors reported in Table 5 . The mrT stage and the mrNode status were significant pCRM involvement predictors on univariate but not on multivariate regression analysis. Four significant factors were evident on multivariate regression analysis: an unsafe mrLRP, MRI anterior quadrant tumor invasion, an MRI tumor height less than 4.0 cm from the anal verge, and mrEMVI. The respective score weightings for these factors were 1.23, 1.00, 1.20, and 1.30. The respective 95% CIs, based on 5000 bootstrap samples, were 1.4 to 11.3; 1.1 to 8.0; 1.4 to 11.0; and 1.3 to 10.8. The model fitted the data well, as evidence by the Hosmer-Lemeshow statistic (x 2 ¼ 6.23, df ¼ 6, P ¼ 0.398). 25 The c-index or area under the curve on receiver operating characteristic analysis was 0.82 (95% CI, 0.74-0.90), which suggests that the model is strongly predictive for pCRM involvement. 26 Probabilities derived from multivariate regression analysis are reported as a percentage risk of pCRM involvement in Table 6 . Of the 279 patients, 176 (63%) had 1 risk factor or less and were at low risk FIGURE 3. The MERCURY II study profile. Ã Preoperative therapy indicated by plane safety and adverse MRI features (!mrT3c, mrN2 and mrEMVI). yTwelve patients were mrEMVIþve or mrN2þve with a safe mrLRP and received no preoperative therapy. zForty-eight patients with no adverse radiological features received preoperative therapy. §Twenty-one patients with an unsafe mrLRP received no preoperative therapy. ôGood response-ymrLRP 'safe' and mrTRG1&2. Poor response-ymrLRP 'unsafe' or mrTRG 3-5.
(risk <5%) for pCRM involvement, 70 (25%) patients had 2 risk factors and were at intermediate risk (risk 5-15%), and 33 (12%) patients had 3 or all 4 risk factors and were at high risk (risk >15%). The results imply that tumors less than 4.0 cm from the anal verge with an unsafe mrLRP have a 12.6% pCRM involvement risk. If the tumor was also anterior, the pCRM risk increased to 28.6%; this high pCRM risk is despite the fact that 77% (13 of 17) of patients were receiving preoperative therapy and 77% receiving an ELAPE (n ¼ 9) or exenteration (n ¼ 4). These high pCRM involvement figures, along with the unsafe ymrLRP data in Table 3 , suggest that high-risk patients may require treatment beyond CRT and an ELAPE.
DISCUSSION
In this prospective, multicenter, international study, the MRI low rectal cancer plane (mrLRP) can reliably assess the extent of tumor invasion and predict for pCRM involvement. Furthermore, in this multicenter setting, through standardized and better preoperative staging, we have achieved our stated objective of appropriately selecting the correct plane of surgery and guiding use of preoperative therapy. This enabled optimal clinical management, which led to reduced pCRM involvement to 9.0%, a marked improvement on previously published low rectal cancer results, [3] [4] [5] and meets the primary objective of reducing pCRM involvement to 15% or less. Thus, an improved approach to low rectal cancer treatment potentially eliminated a significant proportion of preventable pelvic recurrences.
A Safe Low Rectal Plane on Baseline MRI (Safe mrLRP)
Almost half (44.4%; 124/279) of study participants had a safe mrLRP and no adverse MRI features. The recommended management was to proceed straight to surgery with intersphincteric resection, encouragingly adhering to this guidance (50%) led to a clear pCRM in 98% of cases. Added clinical concern may result in these low-risk patients being offered CRT or an ELAPE; however, this resulted in a higher pCRM involvement. Additional treatment and more radical surgery did not result in a benefit to the patient and may represent overtreatment. Therefore, when the baseline mrLRP is safe, with no other risk factors and optimal TME dissection is anticipated, it is feasible and safe to avoid the morbidity of CRT or an extralevator resection by offering sphincter-preserving surgery alone.
Posttreatment MRI Low Rectal Plane Assessment (ymrLRP)
The majority of patients with an MRI unsafe surgical plane received CRT (81.4%) as recommended. Favorable tumor regression occurred in 29.2% (33/113) of patients. The operative strategy varied from local excision to exenteration, but notably among these ''good responders,'' there were no cases of pCRM involvement. The plane of surgery became less radical in 8 (24.2%) of these 33 patients (local excision: n ¼ 1; anterior resection: n ¼ 6; intersphincteric resection: n ¼ 1) than in the initial plan for an ELAPE. Furthermore, 5 patients who initially entered the study were excluded from analysis because of deferral of surgery, all of whom had no evidence of regrowth at 1year follow-up. Contrary to current consensus, 27 this emphasizes the importance of restaging the primary tumor with a willingness to selectively change the initial plan.
On the contrary, almost 25% of ymrLRP unsafe patients developed pCRM involvement (Table 3 ). Routinely offering CRT and an ELAPE to this high-risk group does not appear to be sufficient. To improve pCRM involvement, efforts are required to preoperatively determine specific factors that cause individuals to become at high risk and to offer patient-tailored management such as carefully planned exenterative surgery and optimal preoperative therapy.
Additional Risk Factors for pCRM Involvement
After validating the role of mrLRP in predicting pCRM involvement, additional MRI predictors were investigated by multiple regression analysis. Three other key risk factors were identified: anterior quadrant tumor invasion, mrEMVI, and tumor height.
Tumors less than 4 cm from the anal verge carry a 3.4-fold increased pCRM involvement risk; however, in the absence of additional risk factors, the pCRM involvement risk is 4%. Arguably, these are precisely the patients who should avoid radiotherapy to achieve optimal function 28 ; equally with suitable CRT, there is a reported 19% to 50% chance of an excellent clinical and radiological response that may enable deferral of surgical. 29, 30 Each approach requires careful patient discussion, and deferral of surgery or 'watchful waiting' should be performed in the context of a clinical trial. 31 Overall pCRM involvement was 2.8-fold more likely in the 35% of tumors with anterior quadrant invasion. This supports findings by West and colleagues 15, 32, 33 that even the wider excision The straight to surgery data are adjacent to posttreatment data, with posttreatment values reported in square brackets.
Ã
The operations performed are reported in Figure 3 . The ''y'' value denotes posttreatment report. Preoperative short course radiotherapy was used in 8 cases with 1 involved pCRM, these are shown as superscripted numbers. yMRI adverse features were !mrT3c,mrN2, or mrEMVI.
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produced by an ELAPE still removes relatively less volume anteriorly than in other quadrants. In high-risk cases, an ELAPE may fail to achieve a clear pCRM for these anterior tumors and an anterior compartment exenteration should be considered. The majority of high-risk patients received CRT, yet mrEMVI (19%; 54/279) was associated with a 3.8-fold increased risk of pCRM involvement. Histological EMVI is associated with a poor prognosis (30% 5-year overall survival), high local recurrence, and distant failure rates. 34 In several independent series, mrEMVI also carries a poor prognosis. 12, 35, 36 Perhaps, the high pCRM involvement seen in this group relates to inadequate downstaging in mrEMVI-positive patients. Seemingly, mrEMVI is associated with relative CRT resistance. 36 Although promising early work indicates that after induction chemotherapy, mrEMVI status is more likely to change from positive to negative and better outcomes are observed. 36, 37 Thus, preoperative chemotherapy may be a useful treatment strategy for mrEMVI patients.
Compared with all the assessable low rectal cancer pCRM involvement risk factors outlined earlier, we did not find mrT and mrN stages to be significant on multivariate regression analysis. Therefore, their importance regarding the surgical approach and use of preoperative therapy may be superseded in favor of plane ''safety'' (mrLRP) and the risk factors reported on multivariate regression analysis.
From the patient's perspective, the risk-quantifying model has special relevance. This model improves the information available to health care professionals and patients, which enhances the consent process and increases the likelihood of concordant patient decision making. It may be hypothesized that ''predicted risk'' information will hinder consent by overwhelming the patient. However, a recent Canadian study by Kennedy et al 38 used a threshold decision-making tool to assess the local recurrence risk that patients were willing to take to avoid preoperative therapy. Most patients (84%) changed their choice of treatment depending on the risks presented to them, and many patients accepted surprisingly high risks of recurrence to avoid preoperative therapy. 38 It is therefore feasible to expect the majority of patients to participate in the decision-making process. Long-term outcomes and quality-of-life data are still awaited, and this accumulating data will also provide important information for this discussion and decision-making process.
Limitations
The study was designed to test MRI low rectal cancer plane assessment and the prestated sample size criteria for this primary endpoint were met. However, the quantification model will need validating in independent data sets and prospective implementation to test the impact on oncological outcomes. Finally, although this multicenter study demonstrates the reproducibility of mrLRP, the MERCURY group required exacting standards from highly trained individuals from specialist centers; this implies that results may not be immediately and universally applicable. However, units that were recruited for the MERCURY II study did not wholly represent teaching hospitals and the key to success has been optimal multidisciplinary team (MDT) functioning, which can be achieved by appropriate training. 39 CONCLUSIONS This is the first study to prospectively validate MRI staging of the entire low rectal cancer plane (mrLRP). The use of optimal staging in an MDT setting has aided the decision for preoperative therapy and improved surgical planning, resulting in a significant reduction in pCRM involvement after low rectal cancer surgery. The study findings indicate that mrLRP reporting is required for all low rectal cancers, and in those who have preoperative therapy, posttreatment restaging should be routine.
The commonly used strategy of managing low rectal cancer with CRT and an ELAPE potentially overtreats low-risk patients and The risk of pCRM involvement: green, low risk <5%; amber, intermediate risk 5-15%; red, high risk >15%. The probabilities are calculated from the multivariate model (Table 5) , all values are reported as a predicted percentage (%) risk of pCRM involvement (n ¼ 279).
Ã
The data are based on the preoperative MRI. This would be the posttreatment MRI for patients who received preoperative therapy. undertreats the high-risk group. The pCRM risk stratification model will require further validation in independent data sets, but it has the potential to mark a step forward in low rectal cancer management by providing patient-tailored treatment according to the predicted likelihood of circumferential resection margin involvement.
